First case of breakthrough pneumonia due to Aspergillus nomius in a patient with acute myeloid leukemia

References

• Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses 2009; 52: 206–222.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, . Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644–650.
   PubMed Web of Science ®Google Scholar
• Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007; 153: 1677–1692.
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol 2009; 47: S261–270.
   PubMed Web of Science ®Google Scholar
• Varga J, Frisvad JC, Samson RA. Two new aflatoxin producing species, and an overview of Aspergillus section. Flavi. Stud Mycol 2011; 69: 57–80.
   PubMed Web of Science ®Google Scholar
• Balajee SA, Lindsley MD, Iqbal N, . Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods. J Clin Microbiol 2007; 45: 2701–2703.
   PubMed Web of Science ®Google Scholar
• Ozhak-Baysan B, Alastruey-Izquierdo A, Saba R, . Aspergillus alliaceus and Aspergillus flavus co-infection in an acute myeloid leukemia patient. Med Mycol 2010; 48: 995–999.
   PubMed Web of Science ®Google Scholar
• Paludetti G, Rosignoli M, Ferri E, . Invasive nasosinusal aspergillosis in an immunocompetent patient. Acta Otorhinolaryngol Ital 1992; 12: 581–591 [In Italian].
   PubMedGoogle Scholar
• Schwetz I, Horina J, Buzina W, . Aspergillus oryzae peritonitis in CAPD: case report and review of the literature. Am J Kidney Dis 2007; 49: 701–704.
   PubMedGoogle Scholar
• Manikandan P, Varga J, Kocsubé S, . Mycotic keratitis due to Aspergillus nomius. J Clin Microbiol 2009; 47: 3382–3385.
   PubMedGoogle Scholar
• De Hoog GS, Guarro J, Gené; J, Figueras MJ (eds.), Atlas of Clinical Fungi. Centraalbureau voor Schimmelcultures, Utrecht, NL, 2000.
   Google Scholar
• de Carolis E, Posteraro B, Lass-Flörl C, . Species identification of Aspergillus, Fusarium and Mucorales using direct surface analysis by MALDI-TOF mass spectrometry. Clin Microbiol Infect 2011; Epub ahead of print.
   Google Scholar
• Balajee SA, Houbraken J, Verweij PE, . Aspergillus species identification in the clinical setting. Stud Mycol 2007; 59: 39–46.
   PubMed Web of Science ®Google Scholar
• Balajee SA, Borman AM, Brandt ME, . Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol 2009; 47: 877–884.
   PubMed Web of Science ®Google Scholar
• Posteraro B, Mattei R, Trivella F, . Uncommon Neosartorya udagawae fungus as a causative agent of severe corneal infection. J Clin Microbiol 2011; 49: 2357–2360.
   PubMedGoogle Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, approved standard, document M38-A2, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
   Google Scholar
• Klich MA. Identification of clinically relevant aspergilli. Med Mycol 2006; 44: 127–131.
   PubMed Web of Science ®Google Scholar
• Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 2006; 132: 138–154.
   PubMed Web of Science ®Google Scholar
• Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 2010; 35: 211–218.
   PubMed Web of Science ®Google Scholar
• Lafaurie M, Lapalu J, Raffoux E, . High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 2010; 16: 1191–1196.
   PubMed Web of Science ®Google Scholar
• Bal AM. The echinocandins: three useful choices or three too many? Int J Antimicrob Agents 2010; 35: 13–18.
   PubMed Web of Science ®Google Scholar
• Mayr A, Aigner M, Lass-Flörl C. Caspofungin: when and how? The microbiologist's view. C. Mycoses 2011; 55(1): 27–35.
   PubMedGoogle Scholar
• Madureira A, Bergeron A, Lacroix C, . Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007 30: 551–554.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H, . An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64:1274–1281.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Maertens J, Baila L, . Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45:1227–1233.
   PubMed Web of Science ®Google Scholar
• Nouér SA, Nucci M, Kumar NS, . Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 2011; 53(7): 671–676.
   PubMedGoogle Scholar
• Mokaddas E, Burhamah MH, Ahmad S, Khan ZU. Invasive pulmonary aspergillosis due to Aspergillus terreus: value of DNA, galactomannan and (1- > 3)-beta-D-glucan detection in serum samples as an adjunct to diagnosis. J Med Microbiol 2010; 59:1519–1523.
   PubMedGoogle Scholar
• Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48: 1255–1260.
   PubMed Web of Science ®Google Scholar